title: MRSA new treatments on the horizon: current status.
abstract: There is a choice of anti-MRSA antibiotic available with proven efficacy in the treatment of complicated skin and skin structure infection (cSSSI). Additional anti-MRSA antibiotics are in development, which have the potential to influence how such infections are managed. The emergence of resistance to current anti-MRSA agents, toxicity, and general lack of oral agents with proven efficacy for deep seated infection justify the development of new agents. However, there is a relative dearth of information specific to patients with orthopaedic-related infection. Combination therapy is often used in these patients, although there is a paucity of controlled trial data to support particular antibiotic combinations. As the choice of anti-MRSA agents increases, so does the need to identify which are best for the large variety of infections included in the group of cSSSIs. This is particular true for infections occurring in orthopaedic patients where poorly vascularised tissue, trauma or implanted prosthetic material, pose specific challenges.
authors.affiliation: Department of Microbiology, Leeds Teaching Hospitals and University of Leeds, UK. Mark.Wilcox@leedsth.nhs.uk
authors.forename: M H
authors.initials: MH
authors.lastname: Wilcox
mesh_terms: D000617:Aminoglycosides / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use; D024901:Drug Resistance, Multiple, Bacterial; D004359:Drug Therapy, Combination; D006020:Glycopeptides / Q000627:therapeutic use; D006801:Humans; D000077427:Lipoglycopeptides; D055624:Methicillin-Resistant Staphylococcus aureus; D017192:Skin Diseases, Bacterial / Q000188:drug therapy*; D018461:Soft Tissue Infections / Q000188:drug therapy*; D013203:Staphylococcal Infections / Q000188:drug therapy*; D017334:Teicoplanin / Q000031:analogs & derivatives / Q000627:therapeutic use; D000097583:Ceftaroline; D014640:Vancomycin / Q000031:analogs & derivatives
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D006020:Glycopeptides; D000077427:Lipoglycopeptides; D017334:Teicoplanin; D000097583:Ceftaroline; C469289:dalbavancin; C100708:oritavancin; D014640:Vancomycin; C487637:telavancin